A spokesman for Chinese biopharmaceutical accompany Sinovac Biotech (Sinovac) confirmed on 3 March 2021 that the company's annual production capacity of COVID-19 vaccine can reach two billion doses by June 2021, Reuters news agency reported on Wednesday.
Reportedly, this figure is double Sinovac's prior yearly capacity of one billion doses in the form of bulk ingredient, which the firm had said it could reach by February 2021.
Reuters added that the Global Times, an English-language daily tabloid newspaper under China's state media People's Daily newspaper, had first reported this news, citing a comment from Sinovac's chief executive.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses